Opendata, web and dolomites

Cenya SIGNED

Ex vivo cell labelling for in vivo imaging applied to cell therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Cenya project word cloud

Explore the words cloud of the Cenya project. It provides you a very rough idea of what is the project "Cenya" about.

optimisation    good    surveyed    diseased    gene    optimise    biodistribution    monitor    deal    techniques    validation    hired    possess    cenya    labelling    hurdles    therapeutics    lack    vivo    track    clinical    magic    ex    decide    investment    patients    while    repopulating    time    disease    fallen    unbelievable    market    inhibitors    heart    trials    outlined    tracking    academics    ceo    nearly    opportunity    curing    advent    commercial    monitoring    necessitating    safety    licensing    push    medicine    play    cancer    cell    therapy    tissue    day    bench    40    simpler    staff    size    advisors    labelled    approval    stem    data    recruited    diagnose    modern    bedside    lymphocyte    seeing    annum    gmp    nanoparticle    300m    transferred    suitable    therapies    noninvasive    np    drive    regulatory    cheaper    exclusively    car    checkpoint    treatments    cells    direct    imaging    fda    trafficking    ready    industry    degree    expectations    nps    infusion    faster    multiscale    individual    preclinical    venture    made    sometimes    attractive    agents    lower   

Project "Cenya" data sheet

The following table provides information about the project.

Coordinator
CENYA IMAGING B.V. 

Organization address
address: TWEEDE KOSTVERLORENKADE 11H
city: AMSTERDAM
postcode: 1052RK
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENYA IMAGING B.V. NL (AMSTERDAM) coordinator 150˙000.00

Map

 Project objective

While we do not possess magic, modern day medicine can sometimes approach the unbelievable - curing cancer or repopulating diseased heart tissue; all possible due to the advent of cell therapy. However, cell therapy has fallen far short of expectations. Its success requires the ability to monitor and optimise treatments in real time for each individual; necessitating a direct means of monitoring transferred cells. Noninvasive imaging techniques are essential to the success of modern therapeutics. Here, I will build on my work on developing multiscale GMP-ready imaging nanoparticle (NP) agents with the objective of out-licensing the technology to a new commercial venture, Cenya Imaging, to take this work from the bench to the bedside, and I have recruited an experienced CEO to drive this forward. Advisors have outlined a cheaper, faster and simpler path to regulatory approval for Cenya NPs: labelling cells ex vivo and tracking labelled cells after infusion into patients; since, with this approach, Cenya NPs are used to only track cells and not diagnose a disease, the regulatory hurdles are far lower. Recent developments in cell therapeutics have made tracking of cells a very attractive market; specifically (1) increasing investment in CAR-T cells, checkpoint inhibitors (which affect lymphocyte trafficking), and stem cell therapies (40% per annum growth in phase I trials); (2) regulatory push for increased safety and biodistribution data in trials; and (3) a lack of suitable clinical imaging agents. Market size is estimated at €300M; the FDA recently hired 50 new staff exclusively to deal with cell and gene therapies. We will exploit this new market, while also seeing this as the opportunity to play a significant role in the optimisation of cell therapies. We have surveyed nearly 100 users of cell therapy (preclinical, clinical; academics and industry) to decide on our approach, providing a good degree of validation for our choice of focus.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CENYA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CENYA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More